TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02491918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: cataract surgery in children

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: cataract surgery in children

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens implantation
Description: intraocular lens implantation in the capsular bag or optic capture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens implantation
Description: intraocular lens implantation in the capsular bag or optic capture
Study: NCT01431599

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short-course radiation
Description: 33Gy/10 fractions
Study: NCT01348828

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)
Description: Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
Study: NCT02380417

Intervention type: PROCEDURE
Intervention: paravertebral catheter placement
Description: a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
Study: NCT03173209

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: professional development in Calm Moments Cards program
Description: Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
Study: NCT02380417

Intervention type: PROCEDURE
Intervention: paravertebral catheter placement
Description: a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine

Intervention type: DRUG
Intervention: 0.2% ropivacaine
Description: 0.2% ropivacaine was infused through the elastomeric device

Intervention type: DRUG
Intervention: 0.2% ropivacaine
Description: 0.2% ropivacaine was infused through the elastomeric device

Intervention type: DEVICE
Intervention: Elastomeric pump
Description: An elastomeric pump was connected to the paravertebral catheter

Intervention type: DEVICE
Intervention: Elastomeric pump
Description: An elastomeric pump was connected to the paravertebral catheter
Study: NCT04074187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caplacizumab (ALX-0081)
Description: Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Description: Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
Study: NCT01678287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT04074187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (Methylprednisolone or prednisolone)
Description: Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
Study: NCT01132040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primidone
Description: Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
Study: NCT04074187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (eg, rituximab)
Description: Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
Study: NCT01132040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primidone
Description: Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
Study: NCT04182529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoneuromodulation therapy
Description: low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham, no active stimulation will be given to subjects
Study: NCT03665558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary DDD pacing
Description: Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
Study: NCT02273388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727
Study: NCT02540005

Intervention type: OTHER
Intervention: ROTEM analysis

Intervention type: OTHER
Intervention: ROTEM analysis
Study: NCT02603588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active sphenopalatine ganglion acupuncture
Description: The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham sphenopalatine ganglion acupuncture
Description: The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
Study: NCT00366795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily
Study: NCT00254592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV once a day every 14 days x 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg q 2 wks
Study: NCT00980694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ubiquinol
Description: up to 600 mg per day, oral capsules for 8 weeks
Study: NCT04251104

Intervention type: OTHER
Group type: OTHER
Intervention: Images' personal relevance effectiveness in objective and subjective mood recovery
Description: After completing the PANAS, the negative mood induction phase (viewing a film clip) phase will begin. Before this phase, the participants will be encouraged to experience the feelings generated by the clip as intensely as possible. After viewing the film clip, participants will be asked to complete the PANAS again in order to assess the effectiveness of the negative mood induction procedure.~Following the negative mood induction phase, the emotional recovery phase will be initiated, in which the participants will look at a total of six pictures previously selected according to their experimental condition in order to generate specific positive autobiographical memories. At the end of this phase, participants will once more complete the PANAS in order to assess the effectiveness of the emotional recovery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Images' personal relevance effectiveness in objective and subjective mood recovery
Description: After completing the PANAS, the negative mood induction phase (viewing a film clip) phase will begin. Before this phase, the participants will be encouraged to experience the feelings generated by the clip as intensely as possible. After viewing the film clip, participants will be asked to complete the PANAS again in order to assess the effectiveness of the negative mood induction procedure.~Following the negative mood induction phase, the emotional recovery phase will be initiated, in which the participants will look at a total of six pictures previously selected according to their experimental condition in order to generate specific positive autobiographical memories. At the end of this phase, participants will once more complete the PANAS in order to assess the effectiveness of the emotional recovery.
Study: NCT02270866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNM(trademark) - thermoneuromodulation
Description: The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
Study: NCT00646360

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets daily during pregnancy
Study: NCT04561258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGT103-T
Description: An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGT103-T
Description: An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
Study: NCT03130920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preconditioning
Description: Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preconditioning
Description: Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ.
Study: NCT02089074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug use counselling
Study: NCT04601896

Intervention type: OTHER
Intervention: SF36 questionnaire via telephone interview
Description: SF36 questionnaire via telephone interview

Intervention type: OTHER
Intervention: SF36 questionnaire via telephone interview
Description: SF36 questionnaire via telephone interview
Study: NCT00265317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Study: NCT02045017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide and Dexamethasone
Study: NCT02930889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolization
Description: Prostate Artery Embolization
Study: NCT00265317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Study: NCT03735992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body medicine group program
Description: The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
Study: NCT03306719

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Serial blood sampling

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Serial blood sampling
Study: NCT03475589

Intervention type: DRUG
Group type: OTHER
Intervention: apatinib
Description: Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
Study: NCT00563459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carisbamate
Description: 400-1200 mg/day for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: 200-400mg/day for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: 1000-3000mg/day for 12 months
Study: NCT00438815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)
Study: NCT05767112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplement administation
Description: HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplement administation
Description: HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
Study: NCT04203550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative irrigation
Description: Operation with irrigation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No irrigation
Description: Operation without irrigation
Study: NCT04784286

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine 30-day post-op visit
Description: Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person 30-day post-op visit
Description: Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
Study: NCT03470337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phlogenzym
Description: Bromelain / Trypsin / Rutoside
Study: NCT02654405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate
Description: 6.57 gms of sodium butyrate per day for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules containing approximately 9 mg of sodium butyrate/day
Study: NCT00671645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, bevacizumab
Description: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
Study: NCT02213627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant FSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-hMG
Study: NCT04984824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap duration
Description: A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap duration
Description: A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap duration
Description: A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.
Study: NCT02285673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cell
Study: NCT02531282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
Study: NCT04271904

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Diet
Description: The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week).
Study: NCT01139645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole or Esomeprazole or Lanzoprazole
Description: 1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
Study: NCT04522128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour Change Technique Intervention to Improve Quality of Life
Description: The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behaviour Change Technique Intervention to Improve Quality of Life
Description: The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behaviour Change Technique Intervention to Improve Quality of Life
Description: The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group.
Study: NCT01008605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: delivery system
Description: syringe
Study: NCT03578224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)
Description: Undergo EUS-FNA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration
Description: Undergo FNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid (Perflubutane)
Description: Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
Study: NCT03687554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat GZ/SAR402671
Description: Pharmaceutical form: Hard Capsule Route of administration: Oral